Immunol Feature in Circulation and Thromb in AMI Patients Clinical Trial
— ATAIAOfficial title:
Immunologic Analysis of Aspired Thromb and Circulatory Immune Cell in AMI Patients
Verified date | March 2016 |
Source | Jilin University |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Observational |
Researchers use FCM to analyze the immunol cell feature and its corresponding activation status, as well as the thromb aspirated through the thromb aspiration device in AMI patients
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | April 2018 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 30 Years to 80 Years |
Eligibility |
Inclusion Criteria: - uncomplicated AMI patients Exclusion Criteria: - any self immune disease and recent (within 1 month) or any chronic infection |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jilin University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | immunologic feature of AMI patients | 1 month | No |